Education
About Us
Working with TipRanks
Follow Us
Curis Inc (CRIS)
NASDAQ:CRIS
Earnings Data
Report Date
May 07, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-1.34Last Year’s EPS
-2.05Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 31, 2025
|% Change Since: -46.98%
|Next Earnings Date:May 07, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in drug development with positive clinical data and regulatory advancements, alongside improved financial metrics. However, ongoing net losses and reliance on partnerships present challenges.Company Guidance
During Curis's Fourth Quarter 2024 Business Update Call, significant progress was reported, particularly in the TakeAim Lymphoma study evaluating emavusertib combined with ibrutinib for PCNSL. The study, with over 30 clinical sites open, aims to complete enrollment in 12 to 18 months, targeting accelerated approval pathways in the U.S. and Europe. Among 27 relapsed refractory PCNSL patients, notable responses were observed, including six objective responses in BTKI-experienced patients and five in BTKI-naïve patients. Additionally, the emavusertib study in AML showed a 38% composite CR rate in FLT3 mutation patients, with 10 objective responses in 19 evaluable patients. Financially, Curis reported a net loss of $9.6 million for Q4 2024, down from $117 million in 2023, with cash runway extended into Q4 2025 through recent offerings. The company remains optimistic about future developments and partnerships.Accelerated Approval Pathway for Emavusertib
The discussions with EMA and FDA were productive, leading to the potential for accelerated approval in the U.S. and conditional marketing authorization in Europe for emavusertib in combination with ibrutinib in PCNSL.
Orphan Drug Designation for Emavusertib
Emavusertib has been granted Orphan Drug Designation for primary CNS lymphoma in both the U.S. and Europe.
Positive Clinical Data in NHL and AML
In the TakeAim Lymphoma study, 6 out of 13 BTKI experienced patients and 5 out of 6 BTKI naïve patients showed objective responses. In AML, a 38% composite CR rate was achieved in FLT3 mutation patients.
Financial Improvements
Net loss decreased to $9.6 million in Q4 2024 from $117 million in Q4 2023. R&D and G&A expenses were also reduced.
Extended Cash Runway
Two offerings have extended Curis's cash runway into the fourth quarter of 2025.
---
CRIS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CRIS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 31, 2025 | $2.32 | $2.10 | -9.48% |
| Nov 14, 2024 | $3.93 | $3.98 | +1.27% |
| Aug 01, 2024 | $5.48 | $4.94 | -9.85% |
| May 07, 2024 | $16.17 | $16.20 | +0.19% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Curis Inc (CRIS) report earnings?
Curis Inc (CRIS) is schdueled to report earning on May 07, 2025, TBA Not Confirmed.
What is Curis Inc (CRIS) earnings time?
Curis Inc (CRIS) earnings time is at May 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CRIS EPS forecast?
CRIS EPS forecast for the fiscal quarter 2025 (Q1) is -1.34.
---